^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF inhibitor

    Related drugs:
    2d
    Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer (clinicaltrials.gov)
    P3, N=600, Not yet recruiting, Pfizer
    New P3 trial • Mismatch repair • pMMR
    |
    TP53 (Tumor protein P53)
    |
    Keytruda (pembrolizumab)
    3d
    C6461013: Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Pfizer
    Trial initiation date
    |
    Yervoy (ipilimumab)
    3d
    Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Pfizer
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    sigvotatug vedotin (PF-08046047)
    3d
    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=561, Recruiting, AbbVie
    Trial initiation date • Adverse events • Real-world evidence
    |
    Lucentis (ranibizumab)
    7d
    A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=3, Terminated, Axion Bio, Inc | N=52 --> 3 | Trial completion date: May 2027 --> Apr 2026 | Active, not recruiting --> Terminated; The study was terminated early due to discontinuation of development of the investigational program.
    Enrollment change • Trial completion date • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    9d
    AK112: Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, National University Hospital, Singapore
    New P2 trial
    |
    Yidafan (ivonescimab)
    12d
    Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant (clinicaltrials.gov)
    P=N/A, N=236, Active, not recruiting, AbbVie | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    13d
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=286, Not yet recruiting, Akeso
    New P1/2 trial
    |
    Yidafan (ivonescimab)
    14d
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Erbitux (cetuximab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    15d
    ATMOSPHERE: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (clinicaltrials.gov)
    P2/3, N=671, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lucentis (ranibizumab)
    16d
    Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=216, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jul 2026 --> Sep 2027 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    17d
    C6461008: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer (2025-523524-53-00)
    P1/2, N=50, Not yet recruiting, Pfizer Inc.
    New P1/2 trial
    |
    Yervoy (ipilimumab) • axitinib